Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most ...

Pharmaceutical stocks, including Pfizer (NYSE: PFE) have recently come under scrutiny following President Trump’s executive order directing drugmakers to lower medicine prices to match what ...

Pfizer will produce the drug, which targets lung and colorectal cancers, in the US and take a US$100 million stake in China’s ...

President Donald Trump will sign an executive order Monday to link the cost of drugs to prices abroad, under a so-called ...

Pfizer Inc. (NYSE:PFE) announced it had entered into a licensing agreement valued at approximately $6 billion with Chinese ...

Discover what's behind Pfizer's sharp decline, from post-pandemic revenue drops to halted drug development and regulatory ...

The president has long complained that the United States pays more for medicines than other wealthy countries. But he offered ...

US pharma major Pfizer (NYSE: PFE) is stepping up its presence in the high-stakes field of bispecific immuno-oncology with a licensing deal worth up to $6 billion for a Chinese-developed drug that ...

3SBio will receive an upfront payment of $1.25B and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8B as well as tiered ...